The firm expects third-quarter revenue of $22.62 billion, slightly above consensus, and raised its 2027 forecasts on stronger Zepbound demand.
Recap by typeshit. Full story at TradingView.
The Illinois governor is speaking openly about his own GLP-1 use, saying he wants to end the stigma around the drugs. The post comes from a political fan page on Facebook.
Trell argues a toned lower body comes from lean muscle, crediting weekly strength training and recovery fuel rather than Ozempic or peptides.
The FDA cleared Awiqli as the first weekly insulin for kids 10 and up with type 2 diabetes, and a CagriSema subgroup showed 25% weight loss in women.
A rundown on the pill version of Wegovy, covering what form it comes in and its availability. Thin on details, so tap through for the specifics.
Amgen is also testing dosing as rarely as four to six shots a year. Sweeney says its two pivotal programs are fully enrolled and launch follows once treatment wraps.
Reuters saw the brewer's presentation to hospitality customers. Circana data shows US households with a GLP-1 user spend about 13.5% less on beer.
Loading…